---

Cerebral Stroke & Homeopathy

MD Level Presentation Content

---

SLIDE 1 - Title Slide

• Presented by: [Your Name]
• Department of [Your Department]
• [Institution Name], [Date]

---

SLIDE 2 - Overview / Agenda

1. Introduction & Epidemiology
2. Classification of Stroke
3. Pathophysiology
4. Clinical Features & FAST Mnemonic
5. Diagnosis & Investigations
6. Conventional Management
7. Role of Homeopathy in Stroke
8. Key Homeopathic Remedies (Materia Medica)
9. Evidence Base for Homeopathy in Stroke
10. Integrated Approach & Conclusion

---

SLIDE 3 - Introduction & Epidemiology

• Leading cause of neurological disability worldwide
• ~15 million people affected annually (WHO)
• 5.5 million deaths/year globally
• Up to 10% of elderly develop enough cerebrovascular blockage to cause serious brain dysfunction (Guyton & Hall, Medical Physiology)
• ~25% of people >80 years have had at least one silent brain infarct
• Ischemic stroke: ~80-85% | Hemorrhagic stroke: ~15-20%

• Modifiable: Hypertension (most important), diabetes, hyperlipidemia, smoking, obesity, atrial fibrillation, physical inactivity
• Non-modifiable: Age, sex (male > female), race, family history, prior TIA

---

SLIDE 4 - Classification of Stroke

A. Ischemic Stroke (~80-85%)

B. Hemorrhagic Stroke (~15-20%)

C. TIA (Transient Ischemic Attack)

• Stroke-like symptoms lasting <24 hours (typically <1 hour)
• "Warning stroke" - high risk of major stroke within 48 hours
• ABCD2 score used for risk stratification

---

SLIDE 5 - Pathophysiology

1. Vessel occlusion → Cessation of blood flow
2. Core infarct forms within minutes (CBF <10 mL/100g/min)
3. Ischemic penumbra surrounds core (salvageable tissue)
4. ATP depletion → Ionic pump failure → Na⁺/Ca²⁺ influx
5. Glutamate excitotoxicity → NMDA receptor activation
6. Mitochondrial dysfunction → Free radical generation
7. Inflammation (cytokines, neutrophil infiltration)
8. Apoptosis and necrosis

• Vessel rupture → Hematoma formation
• Mass effect + raised ICP → Herniation
• Blood breakdown products cause cytotoxicity
• Vasospasm in SAH adds secondary ischemia

"Many strokes are caused by arteriosclerotic plaques...activating blood clotting mechanisms, causing a blood clot and blocking blood flow" - Guyton & Hall

---

SLIDE 6 - Clinical Features

FAST Mnemonic (Public Recognition)

• F - Face drooping (unilateral)
• A - Arm weakness
• S - Speech difficulty (slurred/absent)
• T - Time to call emergency

Neurological Deficits by Territory:

Other Symptoms:

• Sudden severe headache (hemorrhagic)
• Nausea, vomiting, loss of consciousness
• Post-stroke depression (very common - up to 33%)

---

SLIDE 7 - Diagnosis & Investigations

• Non-contrast CT brain - Rule out hemorrhage (gold standard initial)
• Blood glucose (r/o hypoglycemia mimicking stroke)
• CBC, coagulation profile (PT/INR, aPTT)
• ECG (AF, MI)

• MRI brain (DWI + ADC) - Most sensitive for early ischemia
• CT/MR Angiography - Vessel occlusion, stenosis
• MR Perfusion - Penumbra mapping

• Echocardiography (cardioembolic source)
• 24-hour Holter monitoring (paroxysmal AF)
• Carotid Doppler

• NIH Stroke Scale (NIHSS) - Severity assessment
• ASPECTS score - CT early ischemic changes

---

SLIDE 8 - Conventional Management

Acute Ischemic Stroke:

• Airway, breathing, circulation
• BP management (permissive hypertension in ischemic)
• Glucose control (target 140-180 mg/dL)
• Temperature management
• DVT prophylaxis

Hemorrhagic Stroke:

• Reverse anticoagulation (if applicable)
• BP target: <140 mmHg systolic
• Surgical evacuation (selected cases)
• Nimodipine for SAH (prevent vasospasm)

Secondary Prevention:

• Antiplatelets (aspirin + clopidogrel)
• Statins (atorvastatin 40-80 mg)
• Anticoagulants for cardioembolic (AF)
• Risk factor modification

---

SLIDE 9 - Homeopathy in Stroke: Theoretical Basis

• Law of Similars (Similia Similibus Curantur)
• Individualization of treatment based on totality of symptoms
• Minimum dose principle
• Dynamic derangement of vital force

• Stroke as a "dynamic derangement" - psycho-neuro-physical phenomenon
• Detailed case-taking: anamnestic history + psychosomatic profiling
• "Tout ensemble" of signs/symptoms determines remedy selection
• Homeopathic remedies used as adjuvant to conventional treatment, not replacement

• Over 100 years ago, homeopathic repertory listed 31 remedies under "Apoplexy" (stroke) rubric
• Including: Arnica, Belladonna, Nux vomica, Opium, Lachesis, Gelsemium, and others

---

SLIDE 10 - Key Homeopathic Remedies: Materia Medica

1. Arnica Montana (Leopard's Bane)

• Indication: Acute phase and recovery; post-trauma, cerebral congestion
• Features: Shock, bruised sensation, aversion to being touched, says "I'm fine" when ill
• Mechanism: Anti-inflammatory, improves microcirculation, reduces edema
• Potency used: 200C and 30C (studied pre- and post-stroke)

2. Belladonna (Deadly Nightshade)

• Indication: Acute hemorrhagic phase; sudden violent onset
• Features: Hot flushed face, throbbing headache, dilated pupils, high fever, delirium
• Key: Right-sided symptoms, worse light/noise/touch

3. Opium (Papaver somniferum)

• Indication: Deep stupor, coma after stroke
• Features: Snoring breathing, dark red face, heavy limbs, complete insensibility
• Key: History of fright, face expressionless

4. Gelsemium (Yellow Jasmine)

• Indication: Recovery phase; paralytic weakness
• Features: Muscular weakness, trembling, drooping eyelids, dizziness, mental dullness
• Key: Weakness out of proportion to actual pathology

5. Nux Vomica (Poison Nut)

• Indication: Post-stroke hemiplegia; spastic paralysis
• Features: Numbness, paralysis of hands/legs, irritability, oversensitivity, insomnia
• Key: Sedentary patients, high-strung personality

6. Lachesis (Bushmaster Snake Venom)

• Indication: Left-sided stroke; hemorrhagic tendency
• Features: Worse on waking/left side, constriction sensations, loquacity, purple face
• Key: Post-menopausal women; morning aggravation

7. Causticum

• Indication: Long-standing post-stroke paralysis
• Features: Progressive, gradual weakness, restless legs, involuntary urination
• Key: Better in damp weather, worse in dry cold

8. Crotalus Horridus (Rattlesnake Venom)

• Indication: Hemorrhagic stroke; malignant hypertension
• Features: Right-sided, easily bleeding, malignant hypertension, jaundiced appearance
• Key: Used alongside Arnica in animal studies

---

SLIDE 11 - Evidence Base: Homeopathy in Stroke

Preclinical Evidence:

• Khuwaja et al. (2014): Arnica montana and Crotalus horridus (30C & 200C) showed neuroprotective effects in rat cerebral ischemia models - prophylactic role demonstrated
• Jonas et al. (1999): Homeopathic Arnica montana with low-dose glutamate showed promise in experimental stroke (rat model)

Clinical Studies:

• Abbas et al. (2018): Open-label pilot study, 50 stroke patients; homeopathy as adjuvant to standard care showed positive outcomes in sequelae management
• Dutta et al. (2023 - RCT): Explore Journal; Individualized homeopathic medicines showed efficacy in post-stroke hemiparesis management (randomized trial)
• Italian study (Integrated Medicine): Homeopathy as part of an integrated approach significantly improved post-stroke rehabilitation outcomes in a public health facility

Systematic Review Context:

• Springer (2025): Complementary therapies for stroke neurorecovery - homeopathy listed among adjuvant therapies with emerging evidence
• Bell IR (2007): Adjunctive CAM modalities in stroke treatment and rehabilitation - published in Topics in Stroke Rehabilitation

Evidence Level Summary:

---

SLIDE 12 - Integrated Approach: Homeopathy + Conventional Medicine

• Standard emergency management takes absolute priority (tPA, thrombectomy)
• Homeopathic adjuvants begin AFTER stabilization
• Arnica montana 200C for cerebral congestion and edema
• Opium/Belladonna for comatose/obtunded patients (individualized)

• Individualized remedy selection based on residual deficits + constitutional type
• Gelsemium/Nux vomica for motor deficits
• Causticum for chronic paralysis
• Alongside conventional rehabilitation (physiotherapy, speech therapy)

• Constitutional homeopathic treatment
• Address post-stroke depression (Ignatia, Natrum muriaticum, Aurum metallicum)
• Lachesis/Nux vomica for personality changes

Homeopathy is an adjuvant in stroke - it does not replace thrombolysis or emergency neurovascular care. Its greatest role is in the rehabilitation and recovery phase.

---

SLIDE 13 - Case Studies (Illustrative)

• 62-year-old male, hypertensive, sudden onset left hemiplegia + headache
• CT: Right basal ganglia ICH
• Conventional: BP control, supportive
• Homeopathy adjuvant: Arnica montana 200C (congestion, aversion to touch) → improved alertness on Day 3

• 55-year-old female, 3 months post left MCA ischemic stroke
• Residual right hemiparesis + expressive aphasia + depression
• Individualized remedy: Causticum (progressive paralysis) + Ignatia (grief/depression)
• Outcome: Improved grip strength + mood improvement over 8 weeks

---

SLIDE 14 - Limitations & Future Directions

• Small sample sizes in clinical trials
• Lack of standardized outcome measures
• Methodological heterogeneity
• Ultra-high dilutions - mechanism not fully explained by conventional science
• Placebo effect cannot always be ruled out

• Large multicentric RCTs (Dutta 2023 is a good starting point)
• Biomarker studies (inflammatory markers, BDNF with homeopathic treatment)
• Neuroimaging correlates of homeopathic neuroprotection
• Standardized case-taking protocols for stroke
• Integration into national rehabilitation guidelines

---

SLIDE 15 - Conclusion

1. Stroke is a medical emergency - "Time is Brain" - conventional management is paramount
2. Ischemic stroke (80-85%) managed with tPA/thrombectomy; hemorrhagic with BP control/surgery
3. Homeopathy has a long tradition in stroke (Apoplexy rubric > 100 years)
4. Arnica montana has the strongest preclinical and clinical evidence
5. The rehabilitation phase offers the greatest scope for homeopathic integration
6. Individualized prescribing based on totality remains the cornerstone
7. Growing evidence base (including an RCT) supports adjuvant homeopathy in post-stroke recovery
8. An integrative, patient-centered model is the way forward

---

SLIDE 16 - References

1. Guyton AC, Hall JE. Textbook of Medical Physiology, 14th ed. Elsevier, 2021
2. Daroff RB et al. Bradley and Daroff's Neurology in Clinical Practice, 8th ed.
3. Ropper AH et al. Adams and Victor's Principles of Neurology, 12th ed.
4. Dutta A et al. Efficacy of Individualized Homeopathic Medicines in Treatment of Post-Stroke Hemiparesis. Explore 2023;19(2):243-250
5. Khuwaja G et al. Protective role of homoeopathic medicines on cerebral ischaemia in animals. Indian J Research Homeopathy 2014;8(4):209-17
6. Abbas A et al. Open-label pilot study: adjuvant homoeopathic medicines in cerebral stroke, 2018
7. Bell IR. Adjunctive CAM in stroke treatment. Topics in Stroke Rehabilitation 2007;14:30-39
8. Springer Nature. Complementary therapies for stroke towards neurorecovery. Discover Medicine 2025

---

IMAGES FOR THE PRESENTATION (Medical Library)

---

Content Summary

---

1. Is the depth appropriate for MD level? (Can add/remove any sections)
2. Any modifications to homeopathic remedies section (more/fewer remedies)?
3. Should I add more case studies or specific potency protocols?
4. Design preference for the PPT (professional dark/light theme, institutional colors)?

---

🧠 CEREBRAL STROKE & HOMEOPATHY

A Comprehensive Academic Presentation | Basic to PhD Level

---

SLIDE 1 - TITLE SLIDE

• Presented by: [Your Name], [Degree/Designation]
• Department of [Practice of Medicine / Materia Medica]
• [Institution Name]
• Date: [Date]

---

SLIDE 2 - TABLE OF CONTENTS

---

MODULE I — INTRODUCTION & EPIDEMIOLOGY

SLIDE 3 - What is Stroke?

• Same symptoms but resolve within 24 hours (usually <1 hour)
• A medical emergency - 10-15% risk of stroke within 3 months
• ABCD2 score used for risk stratification

• "Brain Attack" (paralleling "Heart Attack" for urgency messaging)
• "Apoplexy" (historical/homeopathic literature term)

SLIDE 4 - Epidemiology

• ~15 million strokes per year (WHO)
• 5.5 million deaths annually - 2nd leading cause of death globally
• 5 million left with permanent disability
• Leading cause of neurological disability in the United States (Bradley & Daroff's Neurology)

"Almost all elderly people have blockage of some small arteries in the brain, and up to 10% eventually have enough blockage to cause serious disturbance of brain function... approximately 25% of people greater than 80 years of age have had one or more silent brain infarcts."

• Ischemic stroke: 80-85%
• Hemorrhagic stroke: 15-20% (ICH ~10-15%, SAH ~5%)

---

MODULE II — ANATOMY OF THE CEREBROVASCULAR SYSTEM

SLIDE 5 - Gross Anatomy of the Brain (Basic Level)

• Basal ganglia (caudate, putamen, globus pallidus) - Motor modulation; most common site of hypertensive hemorrhage
• Thalamus - Sensory relay station
• Internal capsule - Dense corticospinal and corticobulbar fibers (small stroke = devastating deficit)
• Brainstem (midbrain, pons, medulla) - CN nuclei, vital centers
• Cerebellum - Coordination, balance, fine motor control

SLIDE 6 - Cerebrovascular Supply: The Arterial System

A. Anterior (Carotid) Circulation - 70% of blood supply

"The brain receives approximately 70% of its blood supply from two internal carotid arteries anteriorly..."

1. Ophthalmic artery → Retinal supply (TIA sign: amaurosis fugax)
2. Posterior communicating artery (PCom) → Connects to basilar
3. Anterior choroidal artery → Internal capsule, choroid plexus
4. Anterior Cerebral Artery (ACA) → Medial frontal & parietal lobes
5. Middle Cerebral Artery (MCA) → Largest branch; lateral hemisphere

• M1: Horizontal (lenticulostriate branches supply basal ganglia/internal capsule)
• M2: Sylvian fissure (opercular branches)
• M3: Cortical (parietal, temporal, frontal branches)
• M4: Distal cortical

B. Posterior (Vertebrobasilar) Circulation - 30% of blood supply

"The vertebral arteries join to form the basilar artery, which then splits to form the two posterior cerebral arteries, which in turn are part of the circle of Willis at the base of the brain." (Medical Physiology, Boron & Boulpaep)

• Posterior inferior cerebellar artery (PICA) → Lateral medulla, cerebellum
• Anterior spinal artery → Anterior spinal cord

• Anterior inferior cerebellar artery (AICA) → Lower cerebellum, pons
• Superior cerebellar artery (SCA) → Upper cerebellum
• Pontine perforators
• Posterior Cerebral Artery (PCA) → Occipital lobes, thalamus, midbrain

SLIDE 7 - Circle of Willis (Circulus Arteriosus Cerebri)

"The connection of the two vertebral arteries forms the basilar artery. The internal carotid arteries and the basilar artery connect to form a vascular loop called the circle of Willis that permits collateral circulation between both the right and left..."

Left ICA ──── AComA ──── Right ICA
     |                        |
    LACA                    RACA
     |                        |
    LMCA                    RMCA
     |                        |
  LPComA                  RPComA
     |                        |
    LPCA ──── Basilar ──── RPCA

• Connects anterior (carotid) and posterior (vertebrobasilar) circulations
• Provides collateral perfusion during arterial occlusion
• Complete circle: Only ~25% of population
• Incomplete circle → No collateral → More severe stroke
• "Substantial variability exists in the anatomy of the circle of Willis, and a significant proportion of individuals may have an incomplete circular loop" (Miller's Anesthesia)

• AComA = most common aneurysm site → SAH
• PCom aneurysm → CN III palsy
• MCA occlusion (most common stroke vessel)

SLIDE 8 - Cerebral Blood Flow: Physiology & Autoregulation (Advanced)

• Normal: 55 mL/100g/min (Adams & Victor's Neurology)
• Critical ischemic threshold: 23 mL/100g/min
• Core infarct zone: <10 mL/100g/min
• Penumbra zone: 10-23 mL/100g/min (salvageable!)

"Over a range of mean blood pressures of approximately 50 to 150 mm Hg, the small pial vessels are able to dilate and to constrict in order to maintain cerebral blood flow (CBF) in a relatively narrow range. This accommodation eventually fails at the extremes of blood pressure, after which CBF follows systemic pressure passively."

• Normal MAP range: 50-150 mmHg → CBF maintained
• Below 50 mmHg → Ischemia
• Above 150 mmHg → Hypertensive encephalopathy, breakthrough edema

• CBF = CPP / CVR
• CPP = MAP - ICP
• Regulated by: PaCO2 (major), PaO2, pH, metabolic demands

• Composed of: Tight junctions between endothelial cells + astrocyte endfeet + pericytes
• Disruption in stroke → Vasogenic edema
• Target for neuroprotection research

SLIDE 9 - Venous Drainage of the Brain

"Three sets of veins drain blood from the brain. The superficial cortical veins are within the pia mater on the brain surface. Deep cortical veins drain the deeper structures of the brain. These veins drain into dural sinuses, of which the superior and inferior sagittal sinuses and the straight, transverse, and sigmoid sinuses are the major dural sinuses. These ultimately drain into the right and left internal jugular veins."

• CVST (Cerebral Venous Sinus Thrombosis) = venous stroke; unique to consider in young women, pregnancy, OCP use, hypercoagulable states
• SSS thrombosis → Bilateral leg weakness (parasagittal infarcts)
• Cavernous sinus thrombosis → Proptosis, ophthalmoplegia, facial pain

---

MODULE III — CLASSIFICATION OF STROKE

SLIDE 10 - Classification

A. Ischemic Stroke (80-85%)

"Many strokes are caused by arteriosclerotic plaques that occur in one or more of the feeder arteries to the brain. The plaques can activate the blood clotting mechanisms, causing a blood clot and blocking blood flow in the artery, thereby leading to an ischemic stroke and acute loss of brain function in a localized area."

B. Hemorrhagic Stroke (15-20%)

"In 15% to 20% of people in whom strokes develop, one of the cerebral blood vessels bursts; hemorrhage then occurs, compressing the local brain tissue and further compromising its functions. The most important risk factor for hemorrhagic stroke is high blood pressure (hypertension)..."

---

MODULE IV — PATHOPHYSIOLOGY

SLIDE 11 - Ischemic Cascade (Molecular Level - PhD)

VESSEL OCCLUSION
       ↓
Cessation of CBF → ATP depletion within 4-5 minutes
       ↓
Na+/K+ ATPase pump failure → Na+ influx, K+ efflux, Cl- influx
       ↓
Cell swelling (cytotoxic edema)
       ↓
Membrane depolarization → Voltage-gated Ca²+ channels open
       ↓
GLUTAMATE EXCITOTOXICITY (massive release)
       ↓
NMDA & AMPA receptor activation → Excessive Ca²+ influx
       ↓
Ca²+ activates: phospholipases, proteases, endonucleases, NOS
       ↓
Mitochondrial dysfunction → ROS (reactive oxygen species) generation
       ↓
Nitric oxide + superoxide → Peroxynitrite (potent oxidant)
       ↓
DNA damage, lipid peroxidation, protein oxidation
       ↓
Inflammation: NF-κB activation → TNF-α, IL-1β, IL-6
Neutrophil infiltration (6-24h) → Further BBB disruption
       ↓
APOPTOSIS (delayed cell death, hours-days)
       ↓
INFARCTION (irreversible cell death)

• Core infarct (CBF <10 mL/100g/min): Irreversible necrosis within minutes
• Penumbra (CBF 10-23 mL/100g/min): Electrically silent but metabolically active - SALVAGEABLE
• Treatment window: Opening of penumbra is the rationale for tPA and thrombectomy

SLIDE 12 - Hemorrhagic Pathophysiology (Advanced)

• Mechanical destruction of neural tissue by hematoma
• Mass effect → Raised ICP → Transtentorial herniation
• Midline shift (>5mm = critical)

1. Hematoma expansion (occurs in 30-40% within first 24h) → CTA "spot sign" predicts this
2. Perihematomal edema → Peaks at 72h, persists weeks
3. Hemoglobin breakdown products (hemosiderin, ferritin, free iron) → Oxidative stress, cytotoxicity
4. Thrombin generation → Proteases activate, BBB disruption
5. Inflammation → Microglial activation, astrocyte reactivity

• Initial ictus → Sudden ICP spike → Global ischemia
• Vasospasm (days 4-14) → Delayed cerebral ischemia in 30% (most preventable complication)
• Nimodipine (calcium channel blocker) prevents vasospasm
• Re-bleeding risk: 10-20% in first 24h if aneurysm unsecured

---

MODULE V — CLINICAL FEATURES & SYNDROMES

SLIDE 13 - Clinical Recognition

FAST Mnemonic (Public Level)

• F - Face drooping (ask to smile - asymmetric?)
• A - Arm weakness (ask to raise both arms - does one drift?)
• S - Speech difficulty (slurred, wrong words, unable to speak?)
• T - Time - call emergency IMMEDIATELY

Extended: BE-FAST (more sensitive)

• B - Balance problems
• E - Eyes (sudden vision loss/double vision)
• • FAST

Cincinnati Prehospital Stroke Scale

SLIDE 14 - Vascular Territory Deficits (Intermediate-Advanced)

SLIDE 15 - Post-Stroke Sequelae

• Hemiplegia/hemiparesis (most common residual)
• Spasticity (upper motor neuron pattern)
• Aphasia (in left hemisphere strokes)
• Cognitive impairment/Vascular dementia
• Dysphagia → Aspiration pneumonia (leading cause of death post-stroke)
• Epileptic seizures (early: within 1 week; late: >1 week)
• Central post-stroke pain (thalamic syndrome)

"Stroke is the leading cause of neurological disability in the United States and one of the most common causes of acquired behavioral changes in adults... interruption of bilateral frontotemporal lobe function is associated with an increased risk of depressive and psychotic symptoms."

• Post-stroke depression: 30-40% (most common neuropsychiatric complication)
• Emotional lability (pathological laughing/crying)
• Anxiety disorders, psychosis
• Vascular dementia (multi-infarct type)

---

MODULE VI — DIAGNOSIS & INVESTIGATIONS

SLIDE 16 - Diagnostic Workup

1. Non-contrast CT brain (NCCT) - First choice; rules out hemorrhage
2. Blood glucose (must rule out hypoglycemia mimicking stroke)
3. CBC, PT/INR/aPTT, electrolytes, renal function
4. ECG - Atrial fibrillation, STEMI
5. Oxygen saturation

• 2D Echocardiography (wall motion abnormality, thrombus, PFO, vegetations)
• Prolonged cardiac monitoring (Holter/implantable loop recorder) - paroxysmal AF
• Carotid Doppler - stenosis

• GFAP (Glial Fibrillary Acidic Protein) - hemorrhagic stroke biomarker
• S100B - astrocytic damage
• NSE (Neuron-specific enolase) - neuronal injury
• NfL (Neurofilament light chain) - axonal damage, prognosis

• NIHSS (0-42) - Stroke severity; >15 = severe
• ASPECTS - Early CT ischemic changes (0-10; <7 = poor thrombectomy candidate)
• mRS (Modified Rankin Scale) - Functional outcome (0=no symptoms, 6=death)

---

MODULE VII — CONVENTIONAL MANAGEMENT

SLIDE 17 - Acute Ischemic Stroke Management

Reperfusion Therapies:

"The mainstay in the reduction of brain injury in the setting of acute ischemic stroke is thrombolysis. Management of thrombolysis has been reviewed in guidelines for the early management of stroke..."

• Window: 4.5 hours from onset
• Dose: 0.9 mg/kg (max 90 mg); 10% bolus, 90% over 60 min
• Contraindications: Active bleeding, BP >185/110, prior ICH, recent surgery, INR >1.7
• NNT: ~8 patients treated to produce 1 additional good outcome

• Window: 24 hours (selected patients with large vessel occlusion - LVO)
• NIHSS ≥6, ASPECTS ≥6, favorable penumbra-core mismatch on CT perfusion
• Superior to tPA alone for LVO
• Devices: Stent retrievers (Solitaire, Trevo), aspiration catheters

Supportive Care:

• Airway: Intubation if GCS ≤8
• BP: Permissive hypertension (allow up to 220/120 unless giving tPA - then maintain <185/110)
• Glucose: Target 140-180 mg/dL (hyperglycemia worsens outcomes)
• Temperature: Treat fever aggressively (every 1°C rise → worse outcome)
• DVT prophylaxis

SLIDE 18 - Secondary Prevention & Hemorrhagic Stroke

• BP target: <130/80 mmHg (chronic)
• HbA1c: <7%
• Lipids: LDL-C <70 mg/dL (or <55 for very high risk)
• Smoking cessation, alcohol moderation, physical activity

• Reverse anticoagulation immediately (PCC, Vitamin K, idarucizumab for dabigatran)
• BP: Target systolic 140-160 mmHg acutely (INTERACT2 trial)
• Surgical hematoma evacuation: Selected cases (posterior fossa ICH, young patients)
• Decompressive craniectomy: Malignant MCA infarction, severe cerebellar stroke
• Nimodipine 60mg q4h × 21 days for SAH (vasospasm prevention)
• Coil/clip aneurysm for SAH

---

MODULE VIII — HOMEOPATHIC THERAPEUTICS

Authentic Materia Medica References

SLIDE 19 - Homeopathic Principles in Stroke (Foundational)

• Diseases represent dynamic derangement of the Vital Force
• Stroke (historically "Apoplexy") was treated by homeopaths using the law of similars
• More than 100 years ago, homeopathic repertory listed 31 remedies under "Apoplexy" rubric:
  • Acon., Apis, Arn., Aster., Bar. c., Bell., Cact., Camph., Caust., Chenop., Cinch., Croc., Crotal., Cupr. m., Formica, Glon., Hydroc. ac., Hyos., Junip. v., Kali br., Kali iod., Lach., Laur., Nux v., Op., Phos., Sep., Stram., Sul., Ver. a., Ver. v.

• After emergency stabilization and CT scan
• Detailed anamnestic history + psychosomatic profiling
• "Tout ensemble" of signs and symptoms determines individualized remedy
• Psycho-neuro-physical totality as the basis of prescription

1. Acute phase: Adjuvant alongside conventional care (not instead of tPA/thrombectomy)
2. Subacute phase: Aid in recovery of neurological deficits
3. Rehabilitation phase: Motor, speech, cognitive recovery
4. Prevention: Constitutional treatment, managing risk factors

---

SLIDE 20 - ARNICA MONTANA (Leopard's Bane)

"In apoplexy, with stertorous respiration (paralysis agg. on left side), or with involuntary stools, with no cerebral excitement, but a heavy stupor, with foul breath; or if the patient should be somewhat conscious he complains of aching soreness over the whole body, fear especially of persons coming towards him, as if they would strike him."

"The face of the Arnica patient is usually cold and pale; in apoplexy paralyzed; in low fevers a dusky red."

• Mind: "After any accident or injury, the patient says he is well, doesn't need a doctor; doesn't want to be touched because of soreness"
• Head: "Hot, with cold body; sensitiveness of brain, with sharp, pinching pains"
• Eyes: "Diplopia from traumatism, muscular paralysis, retinal haemorrhage"
• Ears: "Noises in ear caused by rush of blood to the head"

• Cerebral congestion and hemorrhage in early phase
• Soreness, bruised feeling throughout body
• Stupor without excitement
• Stertorous (noisy) breathing

---

SLIDE 21 - BELLADONNA (Deadly Nightshade - Atropa belladonna)

• Mind: "Acute inflammatory excitement; delirium; wild, violent, raging; sees visions, hallucinations; desires to escape; bites, strikes"
• Head: "Vertigo, with falling to left side or backwards. Much throbbing and heat. Palpitation reverberating in head with labored breathing. Pain, fullness, especially in forehead, also occiput and temples"
• Face: "Red, bluish-red, hot, swollen, shining; convulsive motion of muscles of face"
• Eyes: "Pupils dilated; staring, brilliant; photophobia"

"Belladonna, when the Opium has broken the stupor, and the patient moans, as if conscious of pain, or goes into a convulsion; when there is heat in the head, injected, red appearance of the eyes, and coldness of the extremities."

---

SLIDE 22 - OPIUM (Papaver somniferum)

• Mind: "Patient wants nothing. Complete loss of consciousness; apoplectic state. Frightful fancies, daring, gay, bright. Unable to understand or appreciate his sufferings. Thinks he is not at home. Delirious talking, with wide open eyes."
• Head: "Dull, heavy, stupid. Delirium. Bursting feeling. Complete insensibility; no mental grasp for anything. Paralysis of brain."
• Eyes: "Half-closed, dilated; pupils insensible, contracted. Ptosis. Staring glassy."
• Face: "Red, bloated, swollen, dark suffused, hot. Looks intoxicated, besotted. Spasmodic facial twitching, especially corners of mouth. Veins of face distended. Hanging down of lower jaw."
• Respiration: "Slow, heavy, deep, labored. Cheyne-Stokes breathing. Stertorous. Rattling."

"Opium, when there is stupor and insensibility, more or less complete; heat in the head, coldness in the extremities, and a snoring as in deep sleep."

---

SLIDE 23 - LACHESIS MUTUS (Bushmaster Snake Venom)

"Like all snake poisons, Lachesis decomposes the blood, rendering it more fluid; hence a haemorrhagic tendency is marked."

"Drunkards with congestive headaches and haemorrhoids; prone to erysipelas or apoplexy... Rush of blood to head; after alcohol; mental emotions; suppressed or irregular menses; at climaxis; left-sided apoplexy."

• Character: Cannot bear anything tight anywhere; worse after sleep; worse on left side
• Mind: Talkative, suspicious, jealous; "Loquacity; jumps from one subject to another"
• Head: "Congestion; throbbing, bursting feeling. Heat; worse for sleep and waking. Left-sided headache"
• Tongue: "Trembles; catches on lower teeth when protruded; dry; parched"
• Throat: Cannot bear anything touching neck; worse swallowing

• Left-sided stroke with hemorrhagic tendency
• Post-menopausal women
• Worse on waking from sleep (patient feels unwell on waking)
• Congestive symptoms with dark, venous type bleeding

---

SLIDE 24 - NUX VOMICA (Poison Nut - Strychnos nux-vomica)

• Mind: "Very irritable; sensitive to all impressions. Ugly, malicious. Cannot bear noises, odors, light. Does not want to be touched. Sullen, fault-finding"
• Head: "Vertigo, with momentary loss of consciousness. Intoxicated feeling; worse in morning, mental exertion, tobacco"
• Extremities: "Arms and hands go to sleep. Paresis of arms, with shocks. Legs numb; feel paralyzed; cramps in calves and soles. Partial paralysis, from overexertion or getting soaked (Rhus). Drags his feet when walking. Sensation of sudden loss of power of arms and legs in the morning."

• Post-stroke spastic paralysis
• Hypersensitive, irritable personality
• Paralysis from overwork or exposure to cold
• Wakes 3-4 AM, cannot sleep

---

SLIDE 25 - CAUSTICUM (Potassium Hydrate - Hahnemann's preparation)

• Paralysis: "Local paralysis; vocal cords, tongue, eyelids, face, bladder, extremities. Post-diphtheritic paralysis. Paralysis of single parts. Ptosis. Facial paralysis from cold; from going into cold wind."
• Urinary: "Involuntary urination at night (loss of sphincter control)"
• Extremities: "Unsteady walking; restless legs at night. Heaviness in all limbs"

"Worse: dry, cold winds, in clear fine weather, cold air; from motion of carriage. Better: in damp, wet weather; warmth; heat of bed."

"In chronic ailments and especially in paralytic states, the higher potencies once or twice a week."

• Long-standing post-stroke paralysis (rehabilitation phase)
• Facial nerve palsy from stroke (Bell's palsy-like picture)
• Urinary incontinence post-stroke
• Gradual, progressive weakness - "remittent paralysis"

---

SLIDE 26 - GELSEMIUM SEMPERVIRENS (Yellow Jasmine)

• Mind: "Dull, lazy, apathetic, drowsy; loss of will power. Complete prostration and muscular relaxation"
• Head: "Dizziness, drowsiness, dullness, and trembling. Headache preceded by blindness. Occipital headache"
• Eyes: "Ptosis; eyelids heavy; vision blurred; diplopia"
• Face: "Flushed, besotted. Muscles of jaw and swallowing paralyzed"
• Extremities: "Loss of power of muscular control. Weakness of limbs. Difficulty in placing feet when walking. Excessive trembling and weakness"

• Recovery phase - profound motor weakness out of proportion to findings
• Dysphagia post-stroke
• Blurred/double vision, ptosis
• Mental dullness and apathy

---

SLIDE 27 - CROTALUS HORRIDUS (Rattlesnake Venom)

• Hemorrhagic tendencies; blood non-coagulable
• Right-sided affections predominantly
• Malignant hypertension with stroke tendency
• Besotted, confused expression
• Trembling; tongue paralyzed, can barely protrude

• Hemorrhagic stroke with right-sided paralysis
• Blood disorders with cerebrovascular complications
• Incoagulable blood, dark oozing hemorrhage

---

SLIDE 28 - QUICK REMEDY COMPARISON TABLE

---

MODULE IX — EVIDENCE BASE & RESEARCH

SLIDE 29 - Scientific Evidence: Basic to PhD

A. Preclinical Evidence

• Arnica montana and Crotalus horridus tested at 200C and 30C in rat cerebral ischemia
• Pre-stroke administration: Neuroprotective effect
• Post-stroke (5 days): Improved outcomes
• Conclusion: "These medications may have a potential prophylactic neuroprotective role"

• Homeopathic Arnica montana with low-dose glutamate in experimental stroke (rat model)
• Demonstrated tissue-protective effects

B. Clinical Studies

• 50 stroke patients; homeopathy as adjuvant to standard care
• 27 patients with episode 1 month-1 year ago + 10 with sequelae
• Positive outcomes in rehabilitation phase

• Randomized Controlled Trial - individualized homeopathic medicines in post-stroke hemiparesis
• Significant improvement in motor function vs. control group
• First RCT-level evidence for homeopathy in stroke

• Integrated approach including homeopathy "strongly improves post-stroke rehabilitative performance in a public health facility"

C. Evidence Quality Pyramid for Homeopathy in Stroke

RCT (Dutta 2023)               ← Highest individual study
    ↑
Open-label pilot (Abbas 2018)
    ↑
Animal/preclinical (Khuwaja 2014, Jonas 1999)
    ↑
Case reports, case series (extensive)
    ↑
Classical Materia Medica (>200 years provings)

D. Systematic Review Context

• Springer Nature/Discover Medicine (2025): "Complementary therapies for stroke towards neurorecovery" - homeopathy cited among promising adjuvant therapies
• Bell IR (2007), Topics in Stroke Rehabilitation 14:30-39: "Adjunctive care with nutritional, herbal, and homeopathic CAM modalities in stroke treatment and rehabilitation"
• Chapman et al. (1999) - RCT of homeopathic treatment in mild TBI: Positive outcomes

---

MODULE X — INTEGRATED APPROACH & PROTOCOL

SLIDE 30 - Phase-Wise Integrative Protocol

ACUTE PHASE (0-72 hours) - Conventional Priority

SUBACUTE PHASE (Days 3 - 4 weeks)

• Hemiplegia + spasticity + irritability → Nux Vomica 30C bd
• Hemiplegia + weakness + ptosis + dullness → Gelsemium 30C bd
• Left-sided + hemorrhagic + worsens on waking → Lachesis 200C weekly
• Aphasia + right-sided + Broca's type → Causticum 200C + speech therapy

REHABILITATION PHASE (1 month onwards)

• Constitutional treatment based on miasmatic assessment
• Post-stroke depression: Ignatia amara (grief, sighing), Natrum muriaticum (suppressed grief), Aurum metallicum (hopelessness, deep depression)
• Spastic paralysis (chronic): Causticum 1M weekly
• Vascular dementia: Phosphorus, Alumina, Baryta carbonica
• Personality changes: Nux vomica, Platina, Hyoscyamus

PREVENTIVE/CONSTITUTIONAL LEVEL (PhD-level prescribing)

• Psoric stroke: Fear, anxiety, hypertension; recurring TIAs
• Sycotic stroke: Cholesterol deposits, hypertension, obesity
• Syphilitic stroke: Malignant HTN, hemorrhagic tendency, tissue destruction

---

MODULE XI — LIMITATIONS, FUTURE DIRECTIONS & CONCLUSION

SLIDE 31 - Limitations & Future Research

• Small sample sizes in clinical trials
• Individualized prescribing makes blinded RCTs methodologically challenging
• Mechanism of action at ultra-dilutions not yet fully explained by conventional pharmacology
• Lack of standardized case-taking protocols specific to stroke
• No multicentric, large-scale RCT yet

• Biomarker studies: Do homeopathic remedies modulate GFAP, S100B, BDNF, NfL?
• Neuroimaging correlates: Does Arnica affect penumbra size on MRI perfusion?
• Neuroprotection mechanisms: Heat shock proteins, Nrf2 pathway, mitochondrial protection?
• Epigenetic effects of homeopathic remedies in stroke recovery
• Microbiome-gut-brain axis modulation

1. Large multicentric RCTs (replicating Dutta 2023 at scale)
2. Pragmatic trials in rehabilitation centers
3. Integration into national stroke rehabilitation guidelines
4. Development of standardized stroke-specific homeopathic protocols
5. Mechanistic studies on neuroprotective pathways

SLIDE 32 - Conclusion

• Stroke is a brain attack; FAST recognition saves lives
• Ischemic (clot) vs hemorrhagic (bleed) = different treatments

• Cerebrovascular anatomy determines the clinical syndrome
• Circle of Willis is the collateral lifeline
• "Time is Brain" - 1.9M neurons/minute lost

• Ischemic cascade and penumbra concept justify tPA/thrombectomy
• Secondary prevention and risk factor control = mandatory

• Arnica, Opium, Belladonna = acute phase adjuvants (from authentic Materia Medica)
• Lachesis, Nux vomica, Causticum, Gelsemium = rehabilitation phase
• Growing RCT evidence supports adjuvant homeopathy in post-stroke recovery

• Preclinical neuroprotection evidence is promising
• Individualized prescribing based on miasmatic and constitutional totality
• Integrated model with biomarker and neuroimaging outcomes is the future

"The Vital Force is the curator of the body. Restore it, and healing follows." - Hahnemann

---

SLIDE 33 - REFERENCES

1. Guyton AC, Hall JE. Textbook of Medical Physiology, 14th ed. Elsevier, 2021
2. Ropper AH et al. Adams and Victor's Principles of Neurology, 12th ed. McGraw-Hill, 2019
3. Daroff RB et al. Bradley and Daroff's Neurology in Clinical Practice, 8th ed.
4. Miller RD et al. Miller's Anesthesia, 10th ed. Elsevier, 2020
5. Barash PG et al. Barash, Cullen and Stoelting's Clinical Anesthesia, 9th ed.
6. Boericke W. Pocket Manual of Homeopathic Materia Medica, 9th ed. B. Jain Publishers
7. Allen TF. Handbook of Materia Medica and Homeopathic Therapeutics
8. Allen HC. Materia Medica Keynotes
9. Dutta A et al. Efficacy of Individualized Homeopathic Medicines in Treatment of Post-Stroke Hemiparesis. Explore 2023;19(2):243-250
10. Khuwaja G et al. Protective role of homoeopathic medicines on cerebral ischaemia in animals. Indian J Research Homeopathy 2014;8(4):209-217
11. Bell IR. Adjunctive CAM in stroke treatment and rehabilitation. Top Stroke Rehabil 2007;14:30-39
12. Abbas A et al. Open-label pilot study: adjuvant homoeopathic medicines in cerebral stroke. 2018
13. Jonas W et al. Treatment of experimental stroke with low-dose glutamate and homeopathic Arnica. Perfusion 1999;12:452-62
14. Chapman EH et al. Homeopathic treatment of mild TBI: RCT. J Head Trauma Rehabil 1999;14:521-542
15. Springer Nature. Complementary therapies for stroke towards neurorecovery. Discover Medicine 2025

---

IMAGES AVAILABLE FOR PPT

---

CONTENT SUMMARY: 33 SLIDES | 10 MODULES

---

• Boericke W. Pocket Manual of Homeopathic Materia Medica (exact text quoted)
• Allen TF. Handbook of Materia Medica and Homeopathic Therapeutics (exact text quoted)
• Allen HC. Materia Medica Keynotes (Lachesis - exact text quoted)

1. Any remedy to add/remove (e.g., Gloninum, Phosphorus, Aurum)?
2. Any module to expand or condense?
3. Any design preference for the PPT (dark/light/institutional/saffron-white-green theme)?